Format

Send to

Choose Destination
Anticancer Res. 2018 Oct;38(10):5831-5835. doi: 10.21873/anticanres.12924.

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

Author information

1
The Old Brewery, Winchester Hants, U.K. jnkenyon@doveclinic.com.
2
St George's University of London, London, U.K.

Abstract

BACKGROUND/AIM:

Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients.

PATIENTS AND METHODS:

We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a four-year period.

RESULTS:

Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol.

CONCLUSION:

Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.

KEYWORDS:

Cancer; breast cancer; cannabinoids; ependymoma; prostate cancer

PMID:
30275207
DOI:
10.21873/anticanres.12924
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center